APA (7th ed.) Citation

Y, L., S, R., H, D., Q, Y., KS, M., T, T., . . . TA, G. (2023). Targeting ryanodine receptor type 2 to mitigate chemotherapy-induced neurocognitive impairments in mice. Science translational medicine, 15(715), eadf8977. https://doi.org/10.1126/scitranslmed.adf8977

Chicago Style (17th ed.) Citation

Y, Liu, et al. "Targeting Ryanodine Receptor Type 2 to Mitigate Chemotherapy-induced Neurocognitive Impairments in Mice." Science Translational Medicine 15, no. 715 (2023): eadf8977. https://doi.org/10.1126/scitranslmed.adf8977.

MLA (9th ed.) Citation

Y, Liu, et al. "Targeting Ryanodine Receptor Type 2 to Mitigate Chemotherapy-induced Neurocognitive Impairments in Mice." Science Translational Medicine, vol. 15, no. 715, 2023, p. eadf8977, https://doi.org/10.1126/scitranslmed.adf8977.